Mecure Industries Plc has reported a remarkable turnaround in profitability for the year ended December 31, 2025, with profit after tax (PAT) surging 177% to ₦6.46 billion from ₦2.33 billion the previous year, according to its audited financial statements.
The pharmaceutical manufacturer’s revenue rose 69% year-on-year to ₦77.69 billion in 2025 from ₦46.03 billion in 2024, driven by strong sales across all product categories.
- The acute segment remained the largest contributor, climbing to ₦42.57 billion from ₦25.22 billion.
- OTC products grew to ₦17.31 billion, up from ₦10.26 billion.
- Supplements recorded ₦8.70 billion, while chronic products grew to ₦5.35 billion.
- Revenue from the narcotics segment increased to ₦2.52 billion, and promotional sales rose to ₦1.24 billion.
Total assets stood at ₦81.96 billion as of December 31, 2025, up from ₦54.84 billion in 2024.
The Board of Directors has proposed a 20% dividend payout of earnings per share, equivalent to ₦0.32 per share, subject to shareholder approval, compared with ₦0.15 per share in 2024.
The results highlight stronger operational execution, disciplined cost management, and broad-based revenue growth, contributing to improved margins and enhanced shareholder returns for the year.
